Fig. 6

Disease-specific alterations in USC versus HGSOC tissue specimens. Comparative analysis was performed using differentially expressed proteins in ET versus ES from USC and HGSOC specimens. Proteins passing limma adjusted p < 0.05 with the same pattern of enrichment (i.e., positive or negative LogFC values) across all patients within the respective USC (n = 455 proteins from Additional file 8: Table S3) and HGSOC (n = 796 proteins from Hunt et al. Additional file 8: Table S7 [13]) datasets were prioritized for comparative analyses between serous carcinoma types. The top 5 significantly altered canonical pathways identified by Ingenuity Pathway Analysis (IPA) are highlighted. Drug targets identified by IPA were further crossed with those that are FDA-approved [20]. Canonical pathways and drug targets with positive z-scores (highlighted blue) are elevated in ET, while those with negative z-scores (highlighted red) are elevated in ES